source
- Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceAfter the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…
- Samsung Biologics to acquire Swiss CDMO PolyPeptide for $1.8 billion, entering peptide API marketSamsung Biologics announced a plan to purchase Swiss contract development and manufacturing organization PolyPeptide for $1.8 billion in cash. The acquisition will extend Samsung Biologics' manufa…